Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.54 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.54 |
| ▸ | CHRNA6 | Q15825 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25499128 | 0.92 | HPGD (0.50) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL25512221 | 0.92 | HPGD (0.50) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL13629811 | 0.91 | SMN1; SMN2 (0.49) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL22549555 | 0.91 | ALDH1A1 (0.65) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL14159244 | 0.90 | HPGD (0.48) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL25499141 | 0.90 | HTT (0.55) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL24003647 | 0.88 | SMN1; SMN2 (0.46) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL24003426 | 0.87 | HPGD (0.46) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL25498586 | 0.87 | HPGD (0.48) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL25498584 | 0.87 | SMN1; SMN2 (0.50) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE48334-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010032856-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | 武田薬品工業株式会社 (JP) | 2010-03-25 | — | — | WO | disclosed |
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | HPGD 830/4885CHRNB2 164/4885CHRNA3 310/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | HPGD 410/4885CHRNB2 517/4885CHRNA3 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.